PH3对糖尿病肾病的影响 (PH3)
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy.
The secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Taichung、台湾、407
- Taichung Veterans General Hospital
-
Taipei、台湾
- Taipei Veterans General Hospital
-
Taipei、台湾、114
- Tri-Service General Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Males and Females between 18 and 70 years of age with type 1 or type 2 diabetes
- Sitting blood pressure of <=140/90 mm Hg
- Serum creatinine <=2.0 mg/dL
- Urinary albumin: creatinine ratio between 30 mg/g to 1000 mg/g creatinine (of the first urine sample of the day)
- Hemoglobin A1c <=8%
- Women of child-bearing potential must test negative in a pregnancy test and take contraception measures to prevent pregnancy and can not be breast-feeding
- Voluntary written consent to participate in this study
Exclusion Criteria:
- History of major cardiovascular or cerebrovascular events within 6 months prior to screening
- History of cancer
- Receiving chronic nonsteroidal anti-inflammatory therapy
- History of diabetic ketoacidosis
- Has clinically significant deviation from normal physical examination findings that, in the principal investigator's judgment, may interfere with the study evaluation or affect subject safety
- Has participated in other investigational trials within 28 days prior to study enrollment
- Has taken herbal medical treatment as prescription medication and/or over-the- counter medication, within 28 days prior to study enrollment.
- Has known allergy to the study drug
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:A
Placebo |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
|
有源比较器:B
250mg active ingredient |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
|
有源比较器:C
500mg active ingredient |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
|
有源比较器:D
1000mg active ingredient |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Urinary Albumin/Creatinine Ratio (UACR)
大体时间:24 weeks
|
Change in urinary albumin/creatinine ratio (UACR) from baseline to Week 24 |
24 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Urine Albumin
大体时间:24 weeks
|
Change in urine albumin level from baseline to Week 24 |
24 weeks
|
|
Serum Creatinine
大体时间:24 weeks
|
Change in serum creatinine level from baseline to Week 24 |
24 weeks
|
|
Estimated Glomerular Filtration Rate (eGFR)
大体时间:24 weeks
|
Change in estimated glomerular filtration rate (eGFR) from baseline to Week 24 |
24 weeks
|
|
HbA1c
大体时间:24 weeks
|
Change in HbA1c from baseline to Week 24 |
24 weeks
|
合作者和调查者
调查人员
- 首席研究员:Wu Chang Yang, MD、Taipei Veterans General Hospital, Taiwan
- 首席研究员:Huey-Herng Sheu, MD, PhD、Taichung Veterans General Hospital
- 首席研究员:Yi-Jen Hung, MD、Tri-Service General Hospital (TSGH)
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- PH-CP016
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.